Recombinant Human CD43 Protein

重组人CD43蛋白 | 重组人白细胞分化抗原43蛋白 | 重组人白细胞唾液酸糖蛋白

CD43 antigen | CD43 | CD43) | Galactoglycoprotein | GALGP | GPL115 | Leukocyte sialoglycoprotein | Leukosialin | LSN | Ly-48 | sialophorin (gpL115 | Sialophorin | SPN

rp184109-10μg

10μg

无动物源

≥95%(SDS-PAGE)

Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN) (By similarity). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4+ T-cells and to a lesser extent by CD8+ T-cells (PubMed:18036228). Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR (PubMed:24328034). Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin. Acts as a T-cell counter-receptor for SIGLEC1 (By similarity). Post-translational: Glycosylated; has a high content of sialic acid and O-linked carbohydrate structures. Phosphorylation at Ser-355 is regulated by chemokines, requires its association with ERM proteins (EZR, RDX and MSN) and is essential for its function in the regulation of T-cell trafficking to lymph nodes. Has a high content of sialic acid and O-linked carbohydrate structures. Cleavage by CTSG releases its extracellular domain and triggers its intramembrane proteolysis by gamma-secretase releasing the CD43 cytoplasmic tail chain (CD43-ct) which translocates to the nucleus. Sumoylated.

Testing in progress

重组表达

24.8 kDa

C-10His

40.1-59.0 kDa, under reducing conditions; 40.0-56.2 kDa, under non-reducing conditions.

HEK293 Accession #: P16150 | HEK293

<1.0 EU/μg

人(Human)

1-253 aa

MATLLLLLGVLVVSPDALGSTTAVQTPTSGEPLVSTSEPLSSKMYTTSITSDPKADSTGDQTSALPPSTSINEGSPLWTSIGASTGSPLPEPTTYQEVSIKMSSVPQETPHATSHPAVPITANSLGSHTVTGGTITTNSPETSSRTSGAPVTTAASSLETSRGTSGPPLTMATVSLETSKGTSGPPVTMATDSLETSTGTTGPPVTMTTGSLEPSSGASGPQVSSVKLSTMMSPTTSTNASTVPFRNPDENSRHHHHHHHHHH

Yes

Yes